Genzyme Corporation

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$188Mgeneral payments (2019-2025)
$3.6Mresearch payments (2019-2025)
107,951clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2019 $26M
2020 $9.7M
2021 $17M
2022 $22M
2023 $30M
2024 $39M
2025 $43M

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Specialties it works with most

Dermatology $32M
Neurology (Psychiatry & Neurology) $21M
Hematology & Oncology $15M
Pulmonary Disease $14M
Allergy & Immunology $13M
Gastroenterology (Internal Medicine) $7.7M

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

ClinicianLocationSpecialtyGeneral payments (2019-2025)
Charles Sawyers New York, NY Hematology & Oncology $1,271,522.00
Alexandra Golant New York, NY Dermatology $1,059,846.86
Raj Chovatiya Chicago, IL Dermatology $902,043.24
Guy Young Bozeman, MT Pediatric Hematology-Oncology $828,788.65
Mario Castro Kansas City, KS Pulmonary Disease $816,575.14
Cedric Franklin Rutland Riverside, CA Critical Care Medicine (Internal Medicine) $793,996.06
Marcjonathan Serota Littleton, CO Dermatology $759,567.12
Jonathan Silverberg Washington, DC Dermatology $723,235.89
Matthew Zirwas Bexley, OH Dermatology $667,339.42
Lawrence Eichenfield San Diego, CA Pediatric Dermatology $652,536.86

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.